RxDoctor Payments DataLook up a doctor →

Kate Wheeler, MD

Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1639121056

Payments from drug & device makers

$24,861in general payments, 2019–2025

Across 750 payments — averaging $33.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$8K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • Corcept Therapeutics$1K
  • Mannkind Corporation$1K
  • plus $10K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)12$8,028
Novo Nordisk94$1,882
Lilly USA, LLC75$1,385
Amgen(2 entities)47$1,272
Corcept Therapeutics44$1,145
Mannkind Corporation51$1,132
Tandem Diabetes Care, Inc.27$1,072
Sanofi-aventis U.S. LLC41$895
Abbott36$768
Insulet Corporation29$753
Xeris Pharmaceuticals, Inc.29$609
Radius Health, Inc.19$575
BETA Bionics, Inc.9$546
Bigfoot Biomedical Inc5$427
Boehringer Ingelheim16$327
IBSA Pharma Inc.18$325
AbbVie17$293
Ascendis Pharma Endocrinology Inc15$269
Astellas Pharma US Inc12$267
Senseonics, Incorporated13$259
Dexcom, Inc.14$244
Madrigal Pharmaceuticals6$199
Amneal Pharmaceuticals LLC10$199
Bayer10$193
Pfizer9$142
Merck13$132
Medtronic(2 entities)6$124
Cequr Corporation4$109
Recordati_rare_diseases_inc.5$103
Shire North American Group Inc6$84
Verity Pharmaceuticals Inc.3$66
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$60
Sequel Med Tech, LLC3$59
Antares Pharma, Inc.3$58
Inspire Medical Systems, Inc.1$57
Amarin Pharma, Inc.3$55
Companion Medical, Inc.1$54
Neurocrine Biosciences, Inc.2$54
Novartis3$51
Dynavax Technologies Corporation2$49
Ultragenyx Pharmaceutical Inc.2$42
Halozyme Inc2$35
Azurity Pharmaceuticals, Inc.2$34
Idorsia Pharmaceuticals US Inc2$33
Vivus LLC3$31
Gilead2$30
GSK2$29
Regeneron Healthcare Solutions, Inc.2$27
EUSA Pharma (US) LLC2$27
Johnson & Johnson2$26
Actelion Pharmaceuticals US, Inc.1$25
Endo Pharmaceuticals Inc.1$25
Lundbeck LLC1$23
Chiesi USA, Inc.1$21
Averitas Pharma Inc.1$20
Kyowa Kirin, Inc.1$20
Avion Pharmaceuticals1$19
Upsher-smith Laboratories LLC1$18
Aegerion Pharmaceuticals, Inc.1$16
Avanir Pharmaceuticals, Inc.1$15

How this compares

$24,861 in reported general payments places this provider in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024
$175,901
Medicare patients
554
Services billed
5,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Atlanta

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →